Jaguar Health Stock Slides Thursday: What's Happening?
Jaguar Health shares are sliding Thursday as equity dilution concerns weigh on the company following a debt-for-equity exchange.
Stocks · News reference
Jaguar Health Announces All Pediatric Participants In Napo Pharmaceuticals' Crosover Clinical Study Have Entered Extension Phase To Get Doses Of Crofelemer To Treat Microvillus Inclusion Disease
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that all randomized pediatric MVID patients in Napo's pivotal crossover clinical trial have entered the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Jaguar Health shares are trading lower after the company converted about $5.05 million of debt into common stock, resulting in shareholder dilution.
Reported Earlier: Jaguar Health Issues 547,898 Common Shares To Streeterville Capital To Retire ~$5.05M Of Outstanding Promissory Note
As previously disclosed, on November 12, 2025, Jaguar Health, Inc. (the "Company") issued and sold to Streeterville Capital, LLC ("Streeterville") a secured promissory note in the original principal
Jaguar Health Files Supplement To Offer Up To ~$9.82M Of Common Stock Under At-The-Market Offering Program
JAGUAR HEALTH, INC.Up to $9,824,188Shares of Common Stock This supplement No. 8 (this "Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, as amended by